vs
Side-by-side financial comparison of Coeptis Therapeutics Holdings, Inc. (COEP) and OSR Holdings, Inc. (OSRH). Click either name above to swap in a different company.
Coeptis Therapeutics Holdings, Inc. is the larger business by last-quarter revenue ($862.0K vs $627.7K, roughly 1.4× OSR Holdings, Inc.). Coeptis Therapeutics Holdings, Inc. runs the higher net margin — -146.5% vs -508.9%, a 362.5% gap on every dollar of revenue.
Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.
COEP vs OSRH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $862.0K | $627.7K |
| Net Profit | $-1.3M | $-3.2M |
| Gross Margin | 94.8% | 41.7% |
| Operating Margin | -230.6% | -605.9% |
| Net Margin | -146.5% | -508.9% |
| Revenue YoY | — | -23.7% |
| Net Profit YoY | 55.1% | -1283.3% |
| EPS (diluted) | $0.05 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $862.0K | — | ||
| Q3 25 | $237.4K | $627.7K | ||
| Q2 25 | $200.7K | $1.1M | ||
| Q1 25 | $62.9K | $761.3K | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | $823.0K | ||
| Q2 24 | $0 | $881.8K | ||
| Q1 24 | $0 | $910.2K |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-2.9M | $-3.2M | ||
| Q2 25 | $-4.3M | $-5.2M | ||
| Q1 25 | $-3.4M | $-11.4M | ||
| Q4 24 | $-2.8M | — | ||
| Q3 24 | $-1.8M | $-231.0K | ||
| Q2 24 | $-3.0M | $-97.3K | ||
| Q1 24 | $-3.0M | $-60.4K |
| Q4 25 | 94.8% | — | ||
| Q3 25 | 81.0% | 41.7% | ||
| Q2 25 | 77.5% | 2.9% | ||
| Q1 25 | 28.2% | 22.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 21.8% | ||
| Q2 24 | — | 26.3% | ||
| Q1 24 | — | 26.3% |
| Q4 25 | -230.6% | — | ||
| Q3 25 | -1043.2% | -605.9% | ||
| Q2 25 | -2252.9% | -460.5% | ||
| Q1 25 | -6452.6% | -383.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -433.4% | ||
| Q2 24 | — | -364.0% | ||
| Q1 24 | — | -362.8% |
| Q4 25 | -146.5% | — | ||
| Q3 25 | -1220.8% | -508.9% | ||
| Q2 25 | -2159.9% | -460.2% | ||
| Q1 25 | -5440.9% | -1496.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -28.1% | ||
| Q2 24 | — | -11.0% | ||
| Q1 24 | — | -6.6% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.58 | $0.12 | ||
| Q2 25 | $-1.17 | — | ||
| Q1 25 | $-1.11 | — | ||
| Q4 24 | $-5.35 | — | ||
| Q3 24 | $-0.05 | $-0.06 | ||
| Q2 24 | $-0.08 | $-0.02 | ||
| Q1 24 | $-0.08 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $676.6K | $2.2M |
| Total DebtLower is stronger | $150.0K | — |
| Stockholders' EquityBook value | $13.6M | $134.2M |
| Total Assets | $16.2M | $177.3M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $676.6K | — | ||
| Q3 25 | $421.7K | $2.2M | ||
| Q2 25 | $990.6K | $1.6M | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $12.2K | ||
| Q2 24 | — | $119.1K | ||
| Q1 24 | — | $3.6K |
| Q4 25 | $150.0K | — | ||
| Q3 25 | $150.0K | — | ||
| Q2 25 | $150.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $150.0K | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $1.7M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | $13.6M | — | ||
| Q3 25 | $10.4M | $134.2M | ||
| Q2 25 | $6.1M | $139.2M | ||
| Q1 25 | $6.5M | $132.3M | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $4.8M | $-5.8M | ||
| Q2 24 | $-442.6K | $-4.9M | ||
| Q1 24 | $-1.1M | $-4.3M |
| Q4 25 | $16.2M | — | ||
| Q3 25 | $14.2M | $177.3M | ||
| Q2 25 | $12.2M | $185.4M | ||
| Q1 25 | $13.5M | $174.6M | ||
| Q4 24 | $8.9M | — | ||
| Q3 24 | $9.0M | $20.9M | ||
| Q2 24 | $4.2M | $20.6M | ||
| Q1 24 | $3.9M | $37.3M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.6M | $-2.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.6M | — | ||
| Q3 25 | $-2.2M | $-2.7M | ||
| Q2 25 | $-2.4M | $-482.6K | ||
| Q1 25 | $-2.4M | $-64.1K | ||
| Q4 24 | $-6.6M | — | ||
| Q3 24 | $-1.9M | $-686.5K | ||
| Q2 24 | $-1.4M | $-483.2K | ||
| Q1 24 | $-1.9M | $-498.8K |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
